Comparison of metabolic fates of nicotinamide, NAD+ and NADH administered orally and intraperitoneally; characterization of oral NADH

Journal of Nutritional Science and Vitaminology

Volumn 52, Issue 2, 2006, Pages 142-148

  Kimura, Naoko ^a   Fukuwatari, Tsutomu ^a   Sasaki, Ryuzo ^a   Shibata, Katsumi ^a  

^a UNIVERSITY OF SHIGA PREFECTURE   (Japan)

Author keywords

Intraperitoneal administration; Mouse; NAD+; NADH; Oral administration

Indexed keywords

1 METHYL 6 OXONICOTINAMIDE; 1 METHYLNICOTINAMIDE; N 1 METHYL 4 PYRIDONE 3 CARBOXAMIDE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE N OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CHEMICAL STRUCTURE; CONTROLLED STUDY; DIGESTIVE SYSTEM; FOOD COMPOSITION; FOOD INTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INCUBATION TIME; MALE; MOUSE; NONHUMAN; PH; URINALYSIS;

ACIDS; ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EATING; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED ICR; MOLECULAR STRUCTURE; NAD; NIACINAMIDE; OXIDES; SOLUTIONS;

EID: 33744956871     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.52.142     Document Type: Article

References (23)

1. Gross CJ, Henderson LM. 1983. Digestion and absorption of NAD by the small intestine of the rat. J Nutr 113: 412-420.
2. Henderson LM, Gross CJ. 1979. Transport of niacin and niacinamide in perfused rat intestine. J Nutr 109: 646-653.
3. Shibata K, Kakehi H, Matsuo H. 1990. Niacin catabolism in rodents. J Nutr Sci Vitaminol 36: 87-98.
4. Lowry OH, Passonneau JV, Rock MA. 1961. The stability of pyridone nucleotides. J Biol Chem 236: 2756-2759.
5. Birkmayer JG, Vrecko C, Vole D, Birkmayer W. 1993. Nicotinamide adenine dinucleotide (NADH)-a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta Neurol Scand Suppl 146: 32-35.
6. Birkmayer GJ, Birkmayer W. 1989. Stimulation of endogenous L-dopa biosynthesis-a new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH). Acta Neuro Scan 126: 183-187.
7. Swerdlow RH. 1998. Is NADH effective in the treatment of Parkinson's disease? Drug Aging 13: 263-268.
8. Vrecko K, Storge D, Birkmayer JG, Moller R, Tafeit E, Horejsi R, Reibnegger G. 1997. NADH stimulates endogenous dopamine biosynthesis by enhancing the recycling of tetrahydrobiopterin in rat phaeochromocytoma cell. Biochim Biophys Acta 1361: 59-65.
9. Kazula A, Nowak JZ, Iuvone PM. 1993. Regulation of melatonin and dopamine biosynthesis in chick retina: the role of GABA. Vis Neurosci 10: 621-629.
10. Birkmayer GD, Kay GG, Vurre E. 2002. Stabilized NADH (ENADA) improves jet lag-induced cognitive performance deficit. Wien Med Wochenschr 152: 450-454.
11. Santaella ML, Font I, Disdier OM. 2004. Comparison of oral nicotinamide adenine dinucleotide (NADH) versus conventional therapy for chronic fatigue syndrome. PR Health Sci J 23: 89-93.
12. Forsyth LM, Preuss HG, MacDowell AL, Chiazze L Jr, Birkmayer GD, Bellanti JA. 1999. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol 82: 185-191.
13. 1-methylnicotinamide. J Biol Chem 206: 121-127.
14. 1-methyl-3-pyridone-4-carboxamide, by high-performance liquid chromatography. J Chromatogr 424: 23-28.
15. 1- methylnicotinamide in urine by high-performance liquid chromatography. Vitamins 61: 599-604 (in Japanese).
16. Shibata K. 1989. High-performance liquid chromatographic measurement of nicotinamide N-oxide in urine after extracting with chloroform. Agric Biol Chem 53: 1329-1331.
17. Demarin V, Podobnik SS, Storga-Tomic D, Kay G. 2004. Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study. Drugs Exp Clin Res 30: 27-33.
18. Birkmayer W, Birkmayer GJ, Vrecko K, Mlekusch W, Paletta B, Ott E. 1989. The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of Parkinsonian patients. J Neural Transm Park Dis Dement Sect 1: 297-302.
19. Bushehri N, Jarrell ST, Lieberman S, Mirdamadi-Zonozi N, Birkmayer G, Preuss HG. 1998. Oral reduced B-nicotinamide adenine dinucleotide (NADH) affects blood pressure, lipid peroxidation, and lipid profile in hypertensive rats (SHR). Geriatr Nephrol Urol 8: 95-100.
20. Rex A, Hentschke MP, Fink H. 2002. Bioavailability of reduced nicotinamide-adenine-dinucleotide (NADH) in the central nervous system of the anaesthetized rat measured by laser-induced fluorescence spectroscopy. Pharmacol Toxicol 90: 220-225.
21. Birkmayer JG, Nadlinger K. 2002. Safety of stabilized, orally absorbable, reduced nicotinamide adenine dinucleotide (NADH): a 26-week oral tablet administration of ENADA/NADH for chronic toxicity study in rats. Drugs Exp Clin Res 28: 185-192.
22. Birkmayer JG, Nadlinger KF, Hallstrom S. 2004. On the safety of reduced nicotinamide adenine dinucleotide (NADH). J Environ Pathol Toxicol Oncol 23: 179-194.
23. Rainer M, Kraxberger E, Haushofer M, Mucke HA, Jellinger K A. 2000. No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia. J Neural Transm 107: 1475-1481.